The intestinal epithelial insulin-like growth factor-1 receptor links glucagon-like peptide-2 action to gut barrier function

Endocrinology

Volumn 155, Issue 2, 2014, Pages 370-379

  Dong, Charlotte X ^a   Zhao, Wen ^a   Solomon, Chloe ^a   Rowland, Katherine J ^a   Ackerley, Cameron ^b   Robine, Sylvie ^d   Holzenberger, Martin ^e   Gonska, Tanja ^a,c   Brubaker, Patricia L ^a  

^a UNIVERSITY OF TORONTO   (Canada)

^b HOSPITAL FOR SICK CHILDREN   (Canada)

^c HOSPITAL FOR SICK CHILDREN RESEARCH INSTITUTE   (Canada)

^d CNRS   (France)

^e HÔPITAL SAINT ANTOINE   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CLAUDIN 3; CLAUDIN 7; FLUORESCEIN ISOTHIOCYANATE DEXTRAN; GLUCAGON LIKE PEPTIDE 2; IRINOTECAN; OCCLUDIN; SOMATOMEDIN C RECEPTOR; TIGHT JUNCTION PROTEIN;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CONTROLLED STUDY; ELECTRON MICROSCOPY; ENTERITIS; IMMUNOBLOTTING; INTESTINE EPITHELIUM CELL; INTESTINE MUCOSA PERMEABILITY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; PROTEIN LOCALIZATION; TIGHT JUNCTION; UPREGULATION;

ANIMALS; CLAUDIN-3; CLAUDINS; ENTERITIS; GLUCAGON-LIKE PEPTIDE 2; INTESTINAL MUCOSA; INTESTINES; MICE; MICE, KNOCKOUT; PERMEABILITY; RECEPTOR, IGF TYPE 1; TIGHT JUNCTIONS; UP-REGULATION;

EID: 84893176179     PISSN: 00137227     EISSN: 19457170     Source Type: Journal    
DOI: 10.1210/en.2013-1871     Document Type: Article

References (43)

1. Estall JL, Drucker DJ. Glucagon-like peptide-2. Annu Rev Nutr. 2006;26: 391-411.
2. Rowland KJ, Brubaker PL. The "cryptic" mechanism of action of glucagon-like peptide-2. Am J Physiol Gastrointest Liver Physiol. 2011;301:G1-G8.
3. Jeppesen PB. Modern treatment of short bowel syndrome. Curr Opin Clin Nutr Metab Care. 2013;16: 582-587.
4. Blonski W, Buchner AM, Aberra F, Lichtenstein G. Teduglutide in Crohn's disease. Expert Opin Biol Ther. 2013;13: 1207-1214.
5. Xiao Q, Boushey RP, Drucker DJ, Brubaker PL. Secretion of the intestinotropic hormone glucagon-like peptide 2 is differentially regulated by nutrients in humans. Gastroenterology. 1999;117: 99-105.
6. Yusta B, Huang L, Munroe D, et al. Enteroendocrine localization of GLP-2 receptor expression in humans and rodents. Gastroenterology. 2000;119: 744-755.
7. Guan X, Karpen HE, Stephens J, et al. GLP-2 receptor localizes to enteric neurons and endocrine cells expressing vasoactive peptides and mediates increased blood flow. Gastroenterology. 2006;130: 150-164.
8. Ørskov C, Hartmann B, Poulsen SS, Thulesen J, Hare KJ, Holst JJ. GLP-2 stimulates colonic growth via KGF, released by subepithelial myofibroblasts with GLP-2 receptors. Regul Pept. 2005;124: 105-112.
9. Shin ED, Estall JL, Izzo A, Drucker DJ, Brubaker PL. Mucosal adaptation to enteral nutrients is dependent on the physiologic actions of glucagon-like peptide-2 in mice. Gastroenterology. 2005;128: 1340-1353.
10. Li J, Mizukami Y, Zhang X, Jo WS, Chung DC. Oncogenic K-ras stimulates Wnt signaling in colon cancer through inhibition of GSK- 3β. Gastroenterology. 2005;128: 1907-1918.
11. Lee SJ, Lee J, Li KK, et al. Disruption of the murine Glp2r impairs paneth cell function and increases susceptibility to small bowel enteritis. Endocrinology. 2012;153: 1141-1151.
12. Drucker DJ, Erlich P, Asa SL, Brubaker PL. Induction of intestinal epithelial proliferation by glucagon-like peptide 2. Proc Natl Acad Sci U S A. 1996;93: 7911-7916.
13. Brubaker PL, Izzo A, Hill M, Drucker DJ. Intestinal function in mice with small bowel growth induced by glucagon-like peptide-2. Am J Physiol Endocrinol Metab. 1997;272:E1050-E1058.
14. Cheeseman CI. Upregulation of SGLT-1 transport activity in rat jejunum induced by GLP-2 infusion in vivo. Am J Physiol Regul Integr Comp Physiol. 1997;273:R1965-R1971.
15. Benjamin MA, McKay DM, Yang PC, Cameron H, Perdue MH. Glucagon-like peptide-2 enhances intestinal epithelial barrier function of both transcellular and paracellular pathways in the mouse. Gut. 2000;47: 112-119.
16. Cani PD, Possemiers S, Van de Wiele T, et al. Changes in gut mi-crobiota control inflammation in obese mice through a mechanism involving GLP-2-driven improvement of gut permeability. Gut. 2009;58: 1091-1103.
17. Boushey RP, Yusta B, Drucker DJ. Glucagon-like peptide (GLP)-2 reduces chemotherapy-associated mortality and enhances cell survival in cells expressing a transfected GLP-2 receptor. Cancer Res. 2001;61: 687-693.
18. Bahrami J, Yusta B, Drucker DJ. ErbB activity links the glucagonlike peptide-2 receptor to refeeding-induced adaptation in the murine small bowel. Gastroenterology. 2010;138: 2447-2456.
19. Dubé PE, Forse CL, Bahrami J, Brubaker PL. The essential role of insulin-like growth factor-1 in the intestinal tropic effects of glucagon- like peptide-2 in mice. Gastroenterology. 2006;131: 589-605.
20. Rowland KJ, Trivedi S, Lee D, et al. Loss of glucagon-like peptide- 2-induced proliferation following intestinal epithelial insulin-like growth factor-1-receptor deletion. Gastroenterology. 2011;141: 2166-2175.e7.
21. Steed E, Balda MS, Matter K. Dynamics and functions of tight junctions. Trends Cell Biol. 2010;20: 142-149.
22. Huang KF, Chung DH, Herndon DN. Insulinlike growth factor 1 (IGF-1) reduces gut atrophy and bacterial translocation after severe burn injury. Arch Surg. 1993;128:47-53; discussion 53-54.
23. Lorenzo-Zúñiga V, Rodríguez-Ortigosa CM, Bartolí R, et al. Insulin- like growth factor I improves intestinal barrier function in cirrhotic rats. Gut. 2006;55: 1306-1312.
24. el Marjou F., Janssen KP, Chang BH, et al. Tissue-specific and inducible Cre-mediated recombination in the gut epithelium. Genesis. 2004;39: 186-193.
25. Kappeler L,DeMagalhaes FC, Dupont J, et al. Brain IGF-1 receptors control mammalian growth and lifespan through a neuroendocrine mechanism. PLoS Biol. 2008;6:e254.
26. Bijvelds MJ, Bot AG, Escher JC, De Jonge HR. Activation of intestinal Cl- secretion by lubiprostone requires the cystic fibrosis transmembrane conductance regulator. Gastroenterology. 2009;137: 976-985.
27. Li Y, Hansotia T, Yusta B, Ris F, Halban PA, Drucker DJ. Glucagonlike peptide-1 receptor signaling modulates β-cell apoptosis. J Biol Chem. 2003;278: 471-478.
28. Nakao T, Kurita N, Komatsu M, et al. Irinotecan injures tight junction and causes bacterial translocation in rat. J Surg Res. 2012;173: 341-347.
29. Lal-Nag M, Morin PJ. The claudins. Genome Biol. 2009;10:235.
30. Rahner C, Mitic LL, Anderson JM. Heterogeneity in expression and subcellular localization of claudins 2, 3, 4, and 5 in the rat liver, pancreas, and gut. Gastroenterology. 2001;120: 411-422.
31. Fujita H, Chiba H, Yokozaki H, et al. Differential expression and subcellular localization of claudin-7, -8, -12, -13, and -15 along the mouse intestine. J Histochem Cytochem. 2006;54: 933-944.
32. Lei Z, Maeda T, Tamura A, et al. EpCAM contributes to formation of functional tight junction in the intestinal epithelium by recruiting claudin proteins. Dev Biol. 2012;371: 136-145.
33. Ding L, Lu Z, Foreman O, et al. Inflammation and disruption of the mucosal architecture in claudin-7-deficient mice. Gastroenterology. 2012;142: 305-315.
34. Dubé PE, Rowland KJ, Brubaker PL. Glucagon-like peptide-2 activates beta-catenin signaling in the mouse intestinal crypt: role of insulin-like growth factor-I. Endocrinology. 2008;149: 291-301.
35. González-Mariscal L, Tapia R, Chamorro D. Crosstalk of tight junction components with signaling pathways. Biochim Biophys Acta. 2008;1778: 729-756.
36. McRoberts JA, Riley NE. Regulation of T84 cell monolayer permeability by insulin-like growth factors. Am J Physiol. 1992;262: C207-C213.
37. Modica S, Morgano A, Salvatore L, et al. Expression and localisation of insulin receptor substrate 2 in normal intestine and colorectal tumours. Regulation by intestine-specific transcription factor CDX2. Gut. 2009;58: 1250-1259.
38. Suzuki T, Yoshinaga N, Tanabe S. Interleukin-6 (IL-6) regulates claudin-2 expression and tight junction permeability in intestinal epithelium. J Biol Chem. 2011;286: 31263-31271.
39. Little D, Dean RA, Young KM, et al. PI3K signaling is required for prostaglandin-induced mucosal recovery in ischemia-injured porcine ileum. Am J Physiol Gastrointest Liver Physiol. 2003;284: G46-G56.
40. Barmeyer C, Horak I, Zeitz M, Fromm M, Schulzke JD. The interleukin- 2-deficient mouse model. Pathobiology. 2002;70: 139-142.
41. Sigalet DL, Wallace LE, Holst JJ, et al. Enteric neural pathways mediate the anti-inflammatory actions of glucagon-like peptide 2. Am J Physiol Gastrointest Liver Physiol. 2007;293:G211-G221.
42. Wardill HR, Bowen JM. Chemotherapy-induced mucosal barrier dysfunction: an updated review on the role of intestinal tight junctions. Curr Opin Support Palliat Care. 2013;7: 155-161.
43. Jäger S, Stange EF, Wehkamp J. Inflammatory bowel disease: an impaired barrier disease. Langenbecks Arch Surg. 2013;398: 1-12.